Compare BLCO & DLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | DLB |
|---|---|---|
| Founded | 1853 | 1965 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.4B |
| IPO Year | 2022 | 2005 |
| Metric | BLCO | DLB |
|---|---|---|
| Price | $17.15 | $62.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $17.31 | ★ $93.60 |
| AVG Volume (30 Days) | 334.1K | ★ 556.6K |
| Earning Date | 02-18-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.32% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.62 |
| Revenue | ★ $4,976,000,000.00 | $1,349,130,000.00 |
| Revenue This Year | $8.06 | $5.03 |
| Revenue Next Year | $5.79 | $4.02 |
| P/E Ratio | ★ N/A | $23.72 |
| Revenue Growth | ★ 6.23 | 5.92 |
| 52 Week Low | $10.45 | $61.33 |
| 52 Week High | $18.14 | $89.66 |
| Indicator | BLCO | DLB |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 37.53 |
| Support Level | $16.85 | $61.33 |
| Resistance Level | $17.50 | $64.17 |
| Average True Range (ATR) | 0.45 | 1.16 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 56.10 | 36.53 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.